drugset / Trial / NCT05905653

Pharmacokinetic Study of STN1012600 Ophthalmic Solution in Healthy Adult Males Volunteers

NCT05905653

Phase 1 Completed 8 enrolled Santen Pharmaceutical Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the safety and plasma pharmacokinetics of STN1012600 ophthalmic solution 0.002% (1 drop once daily for 7 days) in healthy adult male subjects.

Timeline

Start
2023-05-25
Primary completion
2023-06-21
Completion
2023-06-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Sepetaprost Small molecule 0.002 % Other

Indications

No indication recorded.